


 Cite this: *RSC Adv.*, 2026, 16, 1151

# Engineering $\epsilon$ -polylysine-based photodynamic therapy agents with oxygen carrying and membrane-targeting capabilities for enhanced therapy under hypoxic conditions

 Lianjun Mou,<sup>a</sup> Xiaoyan Lou,<sup>b</sup> Chang Liu,<sup>b</sup> Qian Yuan,<sup>b</sup> Qingmeng Zhang,<sup>\*c</sup> Xilei Xie,<sup>b</sup> Xiaoyun Jiao,<sup>be</sup> Heng Liu<sup>†d</sup> and Jian Zhang<sup>\*be</sup>

Photodynamic therapy (PDT) offers exceptional spatial and temporal precision, minimal invasiveness, and negligible side effects. However, the hypoxic microenvironment of tumors greatly limits the effectiveness of conventional photodynamic therapy (PDT) and severely reduces its therapeutic efficiency. Here, a simple and versatile method for the preparation of PDT nanocomplexes based on  $\epsilon$ -polylysine (PLY-1/2/3) was developed. By covalently combining a photosensitizer 5,10,15,20-tetra (4-carboxyl phenyl) porphyrin ( $H_2TCPP$ ), a biotin-targeting moiety (b-Bio) and an  $O_2$ -carrying agent, perfluorohexanoic acid (PF-HA), the nanocomplex achieved specific targeting of HeLa cell membranes and was capable of efficiently generating cytotoxic singlet oxygen ( $^1O_2$ ) in both normoxic and hypoxic conditions. Furthermore,  $O_2$ -loaded PLY-1 had enhanced PDT efficacy, and it also showed a higher degree of apoptosis than the non- $O_2$ -loaded one. The results provided a facile and general method for the design and preparation of PDT composite against hypoxia.

Received 17th July 2025

Accepted 22nd December 2025

DOI: 10.1039/d5ra05124j

[rsc.li/rsc-advances](https://rsc.li/rsc-advances)

## Introduction

Since cancer endangers human life and health seriously, the research on cancer treatment is of great significance.<sup>1</sup> Compared with traditional modalities such as surgical resection, radiotherapy, or chemotherapy, photodynamic therapy (PDT) has the advantages of super-spatial and temporal resolution, less invasiveness, and smaller side effects.<sup>2,3</sup> Nevertheless, it is subject to photosensitizers, excitation light, and oxygen ( $O_2$ ), which should be requested simultaneously to achieve the killing of cancer cells.<sup>4</sup> In order to improve the efficiency of PDT, a method widely adopted and proved to be effective is to integrate different mono-functional units to molecular skeletons or nano-carriers, and then construct multifunctional composites.<sup>5–8</sup> Most of the reported composites used for PDT are prepared using mesoporous silica,<sup>9–11</sup> metal–

organic frameworks<sup>12,13</sup>, and covalent organic frameworks,<sup>14,15</sup> which are loaded and modified with several functional molecules, respectively. However, the preparation process is complicated with synthesized and modified steps as well as harsh conditions.<sup>16,17</sup> Moreover, the prepared composites often are inclined to cause drug leakage and lead to biological toxicity, which limits further application.<sup>18</sup> Therefore, it is necessary to develop a general method for facile preparation of PDT composites with stable structures and potent efficacy.<sup>19</sup>

As a typical feature of solid tumors, hypoxia results from the lack of oxygen supply, which is induced by the malignant proliferation of cancer cells and the hypoplasia of blood vessels. It is closely related to the occurrence of cancer development, and also limits the efficacy of conventional oxygen consumption therapies such as PDT and sonodynamic therapy.<sup>20–22</sup> On the other hand, most of the existing commercial photosensitizers kill cancer cells by sensitizing  $O_2$  to produce toxic singlet oxygen ( $^1O_2$ ). While the killing effect of these photosensitizers is remarkable only in the normoxic site of the tumor, it is forceless to the hypoxic site.<sup>23</sup> Moreover, a large amount of  $O_2$  will be consumed in the course of PDT treatment, which further aggravates the degree of hypoxia and greatly impairs the efficacy of PDT.<sup>24</sup> Therefore, it is critical to alleviate the hypoxic micro-environment and reduce the hypoxic resistance to enhance the efficacy of PDT.<sup>25–28</sup>

Herein, we have developed a simple and general method to prepare the PDT composites which loaded with different

<sup>a</sup>Department of Pathology, Human University of Medicine General Hospital, Huaihua 418000, China

<sup>b</sup>College of Chemistry, Chemical Engineering and Materials Science, Shandong Normal University, Jinan 250014, China. E-mail: zhangjian12b@mails.ucas.ac.cn

<sup>c</sup>Department of Orthopaedics, Qilu Hospital of Shandong University, Jinan 250012, China. E-mail: zhangqingmeng@email.sdu.edu.cn

<sup>d</sup>Key Laboratory of Reproductive Health Diseases Research and Translation of Ministry of Education, The First Affiliated Hospital, Hainan Medical University, Haikou 571199, China. E-mail: liuheng11b@muh.edu.cn

<sup>e</sup>State Key Laboratory of Molecular Engineering of Polymers, Fudan University, Shanghai 200438, China



amounts of porphyrin (PLY-1/2/3). It was obtained by covalently grafting different functional units to  $\epsilon$ -polylysine as a polypeptide skeleton.  $\epsilon$ -polylysine has many advantages, such as cheap, good water solubility and thermal stability, favorable biocompatibility and degradability *in vivo*. Moreover, it has been used as a drug carrier.<sup>29–31</sup> In the prepared PDT composites, the photosensitizer was 5,10,15,20-tetra (4-carboxyl phenyl) porphyrin ( $H_2$ TCPP), which mediated the production of  $^1O_2$ . Because of the specific binding ability to the biotin receptors on cancer cells,<sup>32</sup> D-biotin (D-Bio) endowed the targeting feature to PLY-1; perfluorohexanoic acid (PF-HA) was served as an oxygen-carrying agent to supply  $O_2$  to relieve the hypoxic dilemma. It was revealed that PLY-1 could target the cell membranes of HeLa cells specifically and produce  $^1O_2$  to kill HeLa cells both in normoxia and hypoxia effectively (Scheme 1). Furthermore,  $O_2$ -loaded PLY-1 had enhanced PDT efficacy. It also showed a higher degree of apoptosis than non- $O_2$ -loaded PLY-1. The results provided a facile and general method for the design and preparation of PDT composite against hypoxia.

## Experimental section

### Materials and methods

The materials, instruments,  $^1O_2$  generation, cell experiment, cytotoxicity assays, live and dead cell staining, and apoptosis test are listed in the SI.

### Synthesis of compound PLY-1

A mixture of 5,10,15,20-tetra (4-carboxyl phenyl) porphyrin ( $H_2$ TCPP, 0.05 mmol, 40.0 mg), *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide hydrochloride (EDC, 0.40 mmol, 76.7 mg), and *N*-hydroxysuccinimide (NHS, 0.40 mmol, 46.1 mg) was dissolved in DMF. The mixture was stirred at room temperature for 4 h in the dark. Subsequently,  $\epsilon$ -polylysine (2.00 mmol, 316.0 mg) dissolved in DMF was added, and the mixture was stirred at 60 °C under argon protection for 4 h, and then the mixture was moved to room temperature for 20 h. At the same time, perfluorohexanoic acid (PF-HA, 0.20 mmol, 72.8 mg) and D-biotin

(D-Bio, 0.01 mmol, 2.5 mg) were respectively activated by reacting with EDC and NHS in argon at 60 °C for 4 h, and stirring at room temperature for 20 h, then added to the above solution. After completion of the reaction, the reaction solution was dialyzed with a regenerated cellulose dialysis bag (MWCO: 1.0 KDa) ( $H_2O$ : EtOH = 3:7) for 72 h, and the dialysate was changed every 4 h. Finally, the PLY-1 was obtained by lyophilization.

## Results and discussion

PLY-1/2/3, which can improve the PDT efficacy in hypoxia, has been designed and prepared by employing  $\epsilon$ -polylysine as the skeleton (Fig. 1a). Specifically,  $H_2$ TCPP, PF-HA, and D-Bio were covalently bonded to  $\epsilon$ -polylysine by amide reaction that was mediated with *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide hydrochloride and *N*-hydroxysuccinimide successively. After dialysis and lyophilization, PLY-1/2/3, which have different  $H_2$ TCPP content, were obtained (Fig. S1–S7).

Firstly, the molecular structure of PLY-1 was characterized and confirmed by nuclear magnetic resonance (NMR) and Fourier transform infrared spectroscopy (FTIR). It could be seen from  $^1H$  NMR that the signal peaks at 3.76 ppm could be attributed to the methine hydrogen ( $-CO-CH(NH_2)-$ ) in the





Fig. 1 (a) The molecular structures of PLY-1/2/3; (b)  $^{19}F$  NMR spectra of (1) PLY-1 and (5) PF-HA in deuterated DMSO; (c) the  $^1H$  NMR spectra of (1) PLY-1; (2)  $\epsilon$ -polylysine; (3) D-Bio and (4)  $H_2$ TCPP in deuterated DMSO.



Scheme 1 The graphic illustration of the preparation and application of PDT composite (PLY-1) based on  $\epsilon$ -polylysine.





PLY-1 also displayed similar phototoxicity to HeLa cells in hypoxia. Furthermore, PLY-1 loaded with O<sub>2</sub> showed stronger lethality to HeLa cells than that without O<sub>2</sub> loading. 2,7-Dichlorofluorescein diacetate (DCFH-DA) was then used to verify the ability of PLY-1 to generate <sup>1</sup>O<sub>2</sub> in HeLa cells. Compared with the blank group and the control groups, only the HeLa cells in the PLY-1 + light group generated bright green fluorescence (Fig. S12), which validated that PLY-1 could produce toxic <sup>1</sup>O<sub>2</sub> with the excitation of 645 nm to kill HeLa cells. To clarify whether this enhancement originates from hypoxia alleviation rather than intrinsic photophysical changes, HIF-1 $\alpha$  expression was quantified under hypoxic conditions. O<sub>2</sub>-loaded PLY-1 significantly downregulated HIF-1 $\alpha$  regardless of light irradiation, indicating effective hypoxia relief (Fig. S13).

To further evaluate the applicability of PLY-1 as a PDT composite, we performed a live/dead cell staining assay (Fig. 5). While HeLa cells in PBS, PBS + light, PLY-1, and PLY-1 + O<sub>2</sub> groups showed strong green fluorescence, the red channel was not significantly enhanced in normoxia and hypoxia. It was demonstrated that PLY-1 had good biosecurity, and the red light with 210 mW cm<sup>-2</sup> did not damage HeLa cells. However, the PLY-1 + light and PLY-1 + O<sub>2</sub> + light groups displayed distinct outputs. It was observed that the fluorescence of the green channel was decreased. Moreover, the weakness of the green channel in PLY-1 + O<sub>2</sub> + light group was more significant than that of PLY-1 + light group. Meanwhile, the red fluorescence channel was significantly enhanced. This meant that <sup>1</sup>O<sub>2</sub> produced by PLY-1 under light mediated the death of HeLa cells. The <sup>1</sup>O<sub>2</sub>-generated capacity of PLY-1 was further

strengthened after O<sub>2</sub>-carrying, and the PDT efficacy was enhanced.

The apoptosis kits (YF488-Annexin V/PI) were implemented to further identify the different apoptosis stages in HeLa cells induced by PLY-1 (Fig. S14). During the course of apoptosis, phosphatidylserine would turn over to the outside of the cell membrane and bind with YF488-annexin V that could not penetrate the cell membrane, then emit green fluorescence, indicating the cells were in the early stage of apoptosis; when the cells were in late necrotic or apoptotic stage, propidium iodide (PI) would penetrate the damaged cell membrane rather than intact cell membrane, and emit red fluorescence. As can be seen in Fig. S14, there were no significant changes in the green fluorescence channel in PBS, PBS + light, PLY-1, and PLY-1 + O<sub>2</sub> groups both in normoxia/hypoxia. However, the red fluorescence channel in the PLY-1 + light and PLY-1 + O<sub>2</sub> + light groups was lighted. In addition, the PLY-1 + O<sub>2</sub> + light group showed stronger fluorescence than the PLY-1 + light group, which not only suggested that PLY-1 had very low dark toxicity, but also indicated that PLY-1 mediated the death of HeLa cells through late apoptosis or cell necrosis. Moreover, PLY-1 + O<sub>2</sub> + light group displayed more HeLa cells in the late apoptotic or necrotic state compared to the PLY-1 + light group, showing a more significant PDT efficacy. This was consistent with the results of MTT and live/dead cell staining assay, and also verified by the flow cytometry (Fig. 6). Compared with PBS (0.80%), PBS + light (1.06%), PLY-1 (1.72%) and PLY-1 + O<sub>2</sub> (3.99%)




Fig. 5 CLSM images of HeLa cells incubated with calcein-AM/PI after different treatments in normoxia and hypoxia, respectively. The treatments included PBS, PBS + light, PLY-1, PLY-1 + light, PLY-1 + O<sub>2</sub> and PLY-1 + O<sub>2</sub> + light groups (PLY-1: 10.0  $\mu$ g mL<sup>-1</sup>, light: 645 nm, 210 mW cm<sup>-2</sup>, 5 min; Calcein-AM excitation source: 488 nm, collection channel: 500–550 nm, PI excitation source: 561 nm, collection channel: 580–650 nm, scale: 250  $\mu$ m).




Fig. 6 Flow cytometry apoptosis assay incubated with Annexin V-FITC and PI after different treatments in normoxia and hypoxia, respectively. The treatments included PBS, PBS + light, PLY-1, PLY-1 + light, PLY-1 + O<sub>2</sub> and PLY-1 + O<sub>2</sub> + light groups (PLY-1: 10.0  $\mu$ g mL<sup>-1</sup>, light: 645 nm, 210 mW cm<sup>-2</sup>, 5 min; FITC excitation source: 488 nm, collection channel: 490–560 nm; PI excitation source: 561 nm, collection channel: 600–680 nm).



groups in normoxia, HeLa cells in PLY-1 + light and PLY-1 + O<sub>2</sub> + light groups showed more apoptosis, and the proportion of cells in late apoptotic or necrotic stage increased to 63.19% and 77.04% respectively. A similar trend was also observed in hypoxia. The ratio was 1.34%, 1.77%, 0.66% and 1.29% in PBS, PBS + light, PLY-1, and PLY-1 + O<sub>2</sub> groups, respectively, and increased to 25.64% and 61.55% in the PLY-1 + light and PLY-1 + O<sub>2</sub> + light groups, indicating that O<sub>2</sub>-carried PLY-1 could induce more HeLa cells to be in the late apoptotic or necrotic stage, regardless of normoxia or hypoxia. Specifically, the enhancement of PDT efficacy in hypoxia was more significant than in normoxia when O<sub>2</sub> was carried by PLY-1.

## Conclusions

In summary, a series of PDT composites (PLY-1/2/3) has been designed and prepared by employing  $\epsilon$ -polylysine as the skeleton. H<sub>2</sub>TCPP served as the photosensitizer; *D*-Bio endowed the targeting ability to the PDT composites; PF-HA could carry O<sub>2</sub> to ameliorate the hypoxic microenvironment. It was shown that PLY-1 had outstanding biocompatibility and could be targeted to the cell membranes of HeLa cells. Moreover, the PDT efficacy of PLY-1 was further enhanced both in normoxia and hypoxia when O<sub>2</sub> was carried. It was highlighted that the design method proposed and adopted in this work is facile and general, which might be employed to deal with the current dilemma of complicated preparation steps for PDT composites. In addition, this work has confirmed the feasibility of this design method and provided a new view for the development of PDT composites. It was also expected to improve the efficacy of PDT against tumors in hypoxia.

## Conflicts of interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

## Data availability

Data will be made available on request.

Supplementary information (SI) is available. See DOI: <https://doi.org/10.1039/d5ra05124j>.

## Acknowledgements

This work was supported by Youth Innovation Science and Technology Program of Higher Education Institution of Shandong Province (2022KJ337), Shandong Provincial Natural Science Foundation (ZR2023MB102), Joint Program on Health Science & Technology Innovation of Hainan Province (WSJK2024MS135, WSJK2025MS204), Open Project of Key Laboratory of Reproductive Health Diseases Research and Translation of the Ministry of Education at Hainan Medical University (HNSZLAB202404) and State Key Laboratory of Molecular Engineering of Polymers (Fudan University).

## References

- 1 D. Sonkin, A. Thomas and B. A. Teicher, *Cancer. Genet.*, 2024, **286**, 18–24.
- 2 X. Dong, Z. Zhang, R. Wang, J. Sun, C. Dong, L. Sun, C. Jia, X. Gu and C. Zhao, *Small*, 2024, **20**, 2309529.
- 3 B. Ran, Z. Wang, W. Cai, L. Ran, W. Xia, W. Liu and X. Peng, *J. the Am. Chem. Soc.*, 2021, **143**, 17891–17909.
- 4 D. E. Dolmans, D. Fukumura and R. K. Jain, *Nat. Rev. Cancer*, 2003, **3**, 380–387.
- 5 J. Liu, Y. Wang, W. Gao, M. Cao, H. Bian, S. Wang, L. Gui, C. Zhao, Y. Gu, Q. Zhong, J. Zheng, L. Zhang and Z. Yuan, *Adv. Funct. Mater.*, 2025, **35**, 2411986.
- 6 J. Lin, M. Cao, S. Wang, X. Wu, Y. Pan, Z. Dai, N. Xu, L. Zuo, J. Liu, Y. Wang, Q. Zhong, Y. Xu, J. Wu, L. Gui, X. Ji, H. Liu and Z. Yuan, *Small*, 2025, **21**, 2408759.
- 7 J. Liu, X. Ou, K. Wang, K. Wang, L. Gui, F. Song, C. Chen, J. W. Y. Lam, Z. Yuan and B. Z. Tang, *Adv. Funct. Mater.*, 2024, **34**, 2410202.
- 8 Z. Zhou, J. Song, L. Nie and X. Chen, *Chem. Soc. Rev.*, 2016, **45**, 6597–6626.
- 9 M. Asif, M. Fakhar-e-Alam, I. Hussain, I. Amjad, G. Abbas and S. Mahmood, *Process Biochem.*, 2024, **148**, 79–103.
- 10 R. Prieto-Montero, T. Arbeloa and V. Martínez-Martínez, *Photochem. Photobiol.*, 2023, **99**, 882–900.
- 11 W. Pan, Y. Ge, Z. Yu, P. Zhou, B. Cui, N. Li and B. Tang, *Chem. Commun.*, 2019, **55**, 5115–5118.
- 12 A. K. Pattnaik, N. Priyadarshini, P. Priyadarshini, G. C. Behera and K. Parida, *Mater. Adv.*, 2024, **5**, 6030–6051.
- 13 G. T. Nash, T. Luo, G. Lan, K. Ni, M. Kaufmann and W. Lin, *J. Am. Chem. Soc.*, 2021, **143**, 2194–2199.
- 14 N. Khan, G. Slathia, K. Kaliya and A. Saneja, *Drug. Discov. Today*, 2023, **28**, 103602.
- 15 L. Zhang, S. Wang, Y. Zhou, C. Wang, X. Z. Zhang and H. Deng, *Angew. Chem., Int. Ed.*, 2019, **58**, 14213–14218.
- 16 Z. Yu, P. Zhou, W. Pan, N. Li and B. Tang, *Nat. Commun.*, 2018, **9**, 5044.
- 17 F. Hu, S. Xu and B. Liu, *Adv. Mater.*, 2018, **30**, 1801350.
- 18 C. M. Janczak and C. A. Aspinwall, *Anal. Bioanal. Chem.*, 2012, **402**, 83–89.
- 19 Z. Zhang, M. Kang, H. Tan, N. Song, M. Li, P. Xiao, D. Yan, L. Zhang, D. Wang and B. Z. Tang, *Chem. Soc. Rev.*, 2022, **51**, 1983–2030.
- 20 X. Cao, M. Li, Q. Liu, J. Zhao, X. Lu and J. Wang, *Small*, 2023, **19**, 2303195.
- 21 P. Zhu, Y. Chen and J. Shi, *ACS Nano*, 2018, **12**, 3780–3795.
- 22 J. N. Liu, W. Bu and J. Shi, *Chem. Rev.*, 2017, **117**, 6160–6224.
- 23 S. Cui, X. Guo, S. Wang, Z. Wei, D. Huang, X. Zhang, T. C. Zhu and Z. Huang, *Pharmaceuticals*, 2024, **17**, 1274.
- 24 X. Feng, Y. Zhang, W. Lin, J. Li, F. Wu, Q. Lu, H. Song, H. Zhang, F. Lan and J. Lu, *Small*, 2025, **21**, 2410214.
- 25 J. Yu, J. Wu, J. Huang, C. Xu, M. Xu, C. Z. H. Koh, K. Pu and Y. Zhang, *Nat. Commun.*, 2025, **16**, 153.
- 26 L. Jia, Y. Hong, X. He, Y. Zhou, L. Ren, H. Du, B. Zhao, B. Qin, Z. Yang and D. Gao, *Chin. Chem. Lett.*, 2025, **36**, 109957.



- 27 A. Sharma, J. F. Arambula, S. Koo, R. Kumar, H. Singh, J. L. Sessler and J. S. Kim, *Chem. Soc. Rev.*, 2019, **48**, 771–813.
- 28 W. Fan, P. Huang and X. Chen, *Chem. Soc. Rev.*, 2016, **45**, 6488–6519.
- 29 Y. Z. Zhao, B. X. Shen, X. Z. Li, M. Q. Tong, P. P. Xue, R. Chen, Q. Yao, B. Chen, J. Xiao and H. L. Xu, *Nanoscale*, 2020, **12**, 15473–15494.
- 30 H. L. Xu, Z. L. Fan, D. L. ZhuGe, B. X. Shen, B. H. Jin, J. Xiao, C. T. Lu and Y. Z. Zhao, *Colloids Surf., B*, 2017, **158**, 295–307.
- 31 H. L. Xu, K. L. Mao, C. T. Lu, Z. L. Fan, J. J. Yang, J. Xu, P. P. Chen, D. L. ZhuGe, B. X. Shen and B. H. Jin, *Biomaterials*, 2016, **107**, 44–60.
- 32 H. Wang, J. Chang, M. Shi, W. Pan, N. Li and B. Tang, *Angew. Chem.*, 2019, **131**, 1069–1073.
- 33 S. Maiti, N. Park, J. H. Han, H. M. Jeon, J. H. Lee, S. Bhuniya, C. Kang and J. S. Kim, *J. Am. Chem. Soc.*, 2013, **135**, 4567–4572.

